BFC Planning’s Monte Rosa Therapeutics GLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$191 Hold
16
– – ﹤0.01% 3357
2026
Q2
$387 Buy
+16
New +$302 ﹤0.01% 3276

Other funds holding GLUE

BFC Planning's GLUE Position: Q3 2026 in Review

BFC Planning held its Monte Rosa Therapeutics (GLUE) position steady in Q3 2026 at 16 shares worth $191. The position accounts for ﹤0.01% of the portfolio, ranked #3357.

BFC Planning first reported a position in GLUE in Q2 2026 and has held it in 2 quarters since. The position peaked at $387 in Q2 2026. 124 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

  • BFC Planning held 16 shares of Monte Rosa Therapeutics worth $191 as of Q3 2026.
  • BFC Planning left its Monte Rosa Therapeutics share count unchanged in Q3 2026.
  • Monte Rosa Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #3357 holding.
  • BFC Planning first reported a position in Monte Rosa Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • BFC Planning's Monte Rosa Therapeutics position peaked at $387 in Q2 2026.
  • 124 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.